Bressa 1989.

Methods	Five‐week, double‐blind, randomised study
Participants	Outpatients fulfilling DSM‐III criteria for major depression, with a score of at least 20 on Hamilton Rating Scale for Depression (HDRS). Age: not stated Exclusion criteria: suicidal ideas, psychosis, seizure disorders, serious cardiac, renal or hepatic disease, alcoholism or drug abuse, use of antidepressant drug with the preceding 14 days, concurrent medication potentially interacting.
Interventions	Fluoxetine: 18 participants Imipramine: 12 participants Fluoxetine dose range: 20‐60 mg/day imipramine dose range: 75‐175 mg/day
Outcomes	HDRS, Clinical Global Impression (CGI) scores
Notes	Funding: unclear
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomised schedule". No other information provided
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Double blind, no further information
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Unclear if raters were independent and unclear if blinding was successful
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Double blind, no further information
Incomplete outcome data (attrition bias) All outcomes	High risk	Number of drop‐out reported, but unclear reasons for dropout. Rating scale scores reported without denominators. Vital signs and side effects not reported
Selective reporting (reporting bias)	Unclear risk	No secondary endpoint scores. No standard deviations reported for HDRS score
Other bias	Unclear risk	Funding: unclear